Search
for
Sort by
Research 91–120 of 1000+
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Epidermal Growth Factor Induces Proliferation of Hair Follicle-Derived Mesenchymal Stem Cells Through Epidermal Growth Factor Receptor-Mediated Activation of ERK and AKT Signaling Pathways Associated with Upregulation of Cyclin D1 and Downregulation of p16
- KGF and EGF signalling block hair follicle induction and promote interfollicular epidermal fate in developing mouse skin
- Directed Expression of Keratin 16 to the Progenitor Basal Cells of Transgenic Mouse Skin Delays Skin Maturation
- Trichomegaly of the eyelashes following treatment with cetuximab
- Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of <i>Retinoblastoma</i> and <i>Trp53</i> Tumor Suppressors
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Drugs and Hair Loss
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Epigen Transgenic Mice Develop Enlarged Sebaceous Glands
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development
- Allopregnanolone promotes proliferation and differential gene expression in human glioblastoma cells
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Genetically modified laboratory mice with sebaceous glands abnormalities
- Ligand‐independent epidermal growth factor receptor hyperactivation increases sebaceous gland size and sebum secretion in mice
- Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Eruption with Topical Recombinant Human Epidermal Growth Factor